

Appl. No. 09/554,465

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method of identifying a binding site domain having the capacity of binding to a predetermined epitope when positioned C-terminal of at least one ~~further~~ second domain in a recombinant bi- or multivalent polypeptide comprising the steps of
 - (a) testing a panel of binding site domains displayed on the surface of a biological display system as part of a fusion protein for binding to a predetermined epitope, wherein said fusion protein comprises ~~an additional~~ (1) a binding site domain, (2) a third domain positioned N-terminal of said binding site domain and (3) an anchoring domain comprising an amino acid sequence that mediates anchoring of the fusion protein to the surface of said display system; and
 - (b) identifying a binding site domain that binds to said predetermined epitope.
2. **(Currently Amended)** The method of claim 1, wherein said binding site domain and said ~~additional~~ third domain are linked by a polypeptide linker disposed between said binding site and said ~~additional~~ third domain, wherein said polypeptide linker comprises a plurality of plural, hydrophilic, peptide-bonded amino acids and connects the N-terminal end of said binding site domain and the C-terminal end of said additional domain.
3. **(Original)** The method of claim 1 or 2, wherein said binding site domain is a pair of V_H-V_L, V_H-V_H or V_L-V_L domains.
4. **(Previously Presented)** The method of claim 1 wherein said display system is a filamentous phage produced by bacteria transfected therewith, a baculovirus expression system, a ribosome based expression system, a bacteriophage lambda display system or a bacterial surface expression system.
5. **(Original)** The method of claim 4 comprising, prior to step (a), the further step of
 - (a") transfecting bacteria with recombinant vectors encoding said fusion proteins.

Appl. No. 09/554,465

6. **(Previously Presented)** The method of claim 1 comprising, prior to step (a"), the further step of
(a') cloning a panel of nucleic acid molecules encoding said binding site domains into a vector.
7. **(Original)** The method of claim 6, wherein said panel of nucleic acid molecules is derived from immune competent cells of a mammal, fish or bird.
8. **(Currently Amended)** The method of claim 1, wherein said ~~additional~~third domain comprises at least 9 amino acids.
9. **(Currently Amended)** The method of claim 8, wherein said ~~additional~~third domain is or is derived from the N2-domain of the gene III product of filamentous phage.
10. **(Previously Presented)** The method of claim 1, wherein said sequence that mediates said anchoring is or is derived from the C-terminal CT-domain of the gene III product of filamentous phage.
11. **(Previously Presented)** The method of claim 1, wherein said bi- or multivalent polypeptide is a bi- or multifunctional polypeptide.
12. **(Currently Amended)** The method of claim 9, wherein said at least one further second domain comprises polypeptide selected from the group consisting of effector proteins having a conformation suitable for biological activity, amino acid sequences capable of sequestering an ion, and amino acid sequences capable of selective binding to a solid support.
13. **(Currently Amended)** The method of claim 12 wherein said effector protein is an enzyme, toxin, receptor, binding site, biosynthetic antibody binding site, growth factor, cell-differentiation factor, lymphokine, cytokine, or hormone, ~~a remotely detectable moiety, or anti-metabolite.~~

Appl. No. 09/564,465

14. **(Original)** The method of claim 12 wherein said sequence capable of sequestering an ion is calmodulin, methallothionein, a fragment thereof, or an amino acid sequence rich in at least one of glutamic acid, aspartic acid, lysine, and arginine.
15. **(Original)** The method of claim 12 wherein said polypeptide sequence capable of selective binding to a solid support is a positively or negatively charged amino acid sequence, a cysteine-containing amino acid sequence, streptavidin, or a fragment of Staphylococcus protein A.
16. **(Original)** The method of claim 13, wherein said receptor is a co-stimulatory surface molecule important for T-cell activation or comprises an epitope binding site or a hormone binding site.
17. **(Original)** The method of claim 16, wherein said co-stimulatory surface molecule is CD80 (B7-1), CD86 (B7-2), CD58 (LFA-3) or CD54 (ICAM-1).
18. **(Original)** The method of claim 17, wherein said epitope binding site is embedded in a pair of V_H - V_L , V_H - V_H or V_L - V_L domains.
19. **(Currently Amended)** The method of claim 3, wherein said pair of domains are connected by a flexible linker, preferably by a polypeptide linker disposed between said domains, wherein said polypeptide linker comprises a plurality of ~~plural, hydrophilic, peptide-bonded~~ amino acids of a length sufficient to span the distance between the C-terminal end of one of said domains and the N-terminal end of the other of said domains when said fusion protein assumes a conformation suitable for binding when disposed in aqueous solution.
20. **(Currently Amended)** The method of claim 1, wherein the identification of said binding site domain comprises the steps of
 - (b') removing said ~~anchoring domain amino acid sequence that mediates anchoring of the fusion protein to the surface of a phage~~ from said fusion protein;

Appl. No. 09/554,465

- (b'') periplasmatically expressing the nucleic acid molecules encoding the remainder of said fusion protein in bacteria; and
- (b''') verifying whether said binding site domain binds to said predetermined epitope.
21. **(Original)** Kit comprising
- (a) a panel of recombinant vectors encoding a panel of fusion proteins as defined in any one of claims 1 to 20; and/or
- (b) a bacterial library transfected with a panel of vectors as defined in (a).
22. **(Currently Amended)** A binding site domain or fusion protein obtainable by the method of claim 1, wherein said binding site domain comprises at least one complementarity determining region (CDR) of the scFv fragment ~~shown in~~ in accordance to any one of figures 6.3 to 6.10 and 7 SEQ ID NOs. 61, 63, 65, 67, 69, 71, 73, 75 and 77.
23. **(Original)** A polypeptide or an antibody comprising at least one binding site domain or fusion protein of claim 22.
24. **(Currently Amended)** The polypeptide or antibody of claim 23 having the amino acid sequence ~~as depicted in~~ in accordance to any one of SEQ ID NOs. 61, 63, 65, 67, 69, 71, 73, 75 and 77 figures 6.3 to 6.10 and 7.
25. **(Original)** Polynucleotides which upon expression encode the polypeptide or antibody of claim 23 or 24.
26. **(Original)** A cell transfected with a polynucleotide of claim 25.
27. **(Original)** A process for the preparation of a polypeptide or antibody of claim 23 or 24 comprising cultivating a cell of claim 26 under conditions suitable for the expression of the polypeptide and isolating the polypeptide from the cell culture medium.

Appl. No. 09/554,465

28. **(Original)** A pharmaceutical composition containing a polypeptide or antibody of claim 23 or 24 and optionally a pharmaceutically acceptable carrier.
29. **(Original)** A diagnostic composition comprising the polypeptide or antibody of claim 23 or 24 and optionally suitable means for detection.
30. **(Previously Presented)** A binding site domain or fusion protein obtainable by the method of claim 1, wherein said binding site domain or fusion protein comprises at least one complementary determining region (CDR) of the scFv fragment shown in figure 6.10.
31. **(Previously Presented)** A polypeptide or an antibody comprising at least one binding site domain or fusion protein of claim 30.
32. **(Currently Amended)** The polypeptide or antibody of claim 23, having the amino acid sequence ~~as depicted in figure 6.10~~ according to SEQ ID No. 75.
33. **(Previously Presented)** The polypeptide of claim 32 having the amino acid sequence according to SEQ ID No. 75.
34. **(New)** A polypeptide or an antibody comprising at least one binding site domain or fusion protein that comprises any one of SEQ ID NOs. SEQ ID NOs. 61, 63, 65, 67, 69, 71, 73, 75 and 77.
35. **(New)** A polypeptide or an antibody comprising at least one binding site domain or fusion protein that comprises SEQ ID NO. 75.